The National Pharmaceutical Pricing Authority (NPPA) has directed State Drug Controllers to closely monitor the implementation of revised prices for 137 non-scheduled anti-cancer drugs, with the aim of ensuring that patients receive the benefits of reduced medicine costs.
The revised prices, introduced under the Trade Margin Rationalisation (TMR) framework, came into effect on November 9, 2026, following a Gazette Order issued on October 17, 2026. The NPPA operates under the Department of Pharmaceuticals.
The latest revised price lists, prepared using company submissions received up to November 11, 2026, are available on the NPPA website and through the Pharma Sahi Daam app and portal.
The authority has directed manufacturers, retailers, dealers, stockists, hospitals and medical institutions to comply with the revised prices. They must also prominently display the updated price lists at their premises and on their websites.
State Drug Controllers to monitor compliance
State Drug Controllers have been instructed to monitor manufacturers, medicine dealers, hospitals and medical institutions to ensure that the revised maximum retail prices (MRPs) are being followed.
The NPPA has warned that violations may lead to proceedings for overcharging under the provisions of the Drugs (Prices Control) Order, 2013 (DPCO).
State Drug Controllers have also been asked to submit their Action Taken Reports to the NPPA by November 16, 2026.
Patients can report overcharging and medicine shortages
Consumers can report complaints involving overcharging, shortages or the non-availability of medicines through the following channels:
- Pharma Sahi Daam: App or online portal
- NPPA helpline: 1800-111-255
- Email: monitoring-nppa@gov.in
The monitoring directive is intended to ensure that the revised prices are implemented across the supply chain and that patients benefit from the price changes.
Read More :